Interview John Soloninka, President & CEO, HTX, Canada
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pediapharm is the first and only speciality pharmaceutical corporation in Canada that exclusively distributes and licenses innovative medicines used to treat pathological conditions that mainly affect children from infancy to eighteen years of age.
Through its network with key stakeholders within the paediatric arena, Pediapharm’s key objective is to partner with leading healthcare entities around the world to bring innovative paediatric products to the Canadian market. By doing so, the company contributes to the improvement of children’s health and quality of life; its partners can thus be assured of long-term commitment and unwavering integrity.
Pediapharm’s unique business model, company values and human capital, set it apart as Canada’s leading paediatric speciality pharmaceutical company.
Contact:
Address: 1 Place du Commerce, Verdun, QC H3E 1A2 Montreal, Canada
Tel.: +1 514 762 2626
Website: http://www.pedia-pharm.com/en/
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas…
David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas…
Wendy Adams, General Manager of Galderma Canada, speaks about the importance of the Canadian market for the global company, what sets Galderma apart from its competitors, and where she sees…
Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister…
Deborah Brown, President of EMD Serono Canada, talks about Canada’s emerging market mentality, despite being a developed country, and how this lack of innovation and risk-taking could ultimately break Canada’s…
The president of Brancorth Medical talks about the challenges of the start-up med tech scene in Canada, turning innovation into corporate success, and the role of the government in creating…
Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its…
Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare…
Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through…
See our Cookie Privacy Policy Here
